{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:59:32Z","timestamp":1764403172558},"reference-count":28,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13444","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T08:09:51Z","timestamp":1658909391000},"source":"Crossref","is-referenced-by-count":9,"title":["Atezolizumab\u2011associated encephalitis in metastatic breast cancer: A case report"],"prefix":"10.3892","volume":"24","author":[{"given":"Guixian","family":"Chen","sequence":"first","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Lan","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Lou","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"key20220826100530_b1-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"key20220826100530_b2-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"key20220826100530_b3-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"key":"key20220826100530_b4-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition","volume":"21","author":"Pan","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"key20220826100530_b5-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"key20220826100530_b6-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"key20220826100530_b7-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"e847","DOI":"10.1016\/j.clgc.2017.03.001","article-title":"Atezolizumab-induced encephalitis in metastatic bladder cancer: A case report and review of the literature","volume":"15","author":"Levine","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"key20220826100530_b8-ol-24-03-13444","first-page":"2050313X18792422","article-title":"Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature","volume":"6","author":"Laserna","year":"2018","journal-title":"SAGE Open Med Case Rep"},{"key":"key20220826100530_b9-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ensci.2018.12.001","article-title":"Atezolizumab-induced encephalitis in metastatic lung cancer: A case report and literature review","volume":"14","author":"Arakawa","year":"2018","journal-title":"eNeurologicalSci"},{"key":"key20220826100530_b10-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/j.cllc.2020.03.006","article-title":"Immune-related encephalitis in two patients treated with immune checkpoint inhibitor","volume":"21","author":"Robert","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"key20220826100530_b11-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13256-020-02411-y","article-title":"Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: A case report","volume":"14","author":"Yamaguchi","year":"2020","journal-title":"J Med Case Rep"},{"key":"key20220826100530_b12-ol-24-03-13444","article-title":"A case of anti-CRMP5 paraneoplastic neurological syndrome induced by atezolizumab for small cell lung cancer","author":"Tatsumi","year":"2020","journal-title":"Intern Med"},{"key":"key20220826100530_b13-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"e2021261","DOI":"10.4322\/acr.2021.261","article-title":"Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: A case report and review of neurological adverse events associated with checkpoint inhibitors","volume":"11","author":"Nader","year":"2021","journal-title":"Autops Case Rep"},{"key":"key20220826100530_b14-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"e26377","DOI":"10.1097\/MD.0000000000026377","article-title":"Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review","volume":"100","author":"\u00d6zdirik","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key20220826100530_b15-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1212\/WNL.0000000000013091","article-title":"Bilateral thalamic lesions associated with atezolizumab-induced encephalitis: A follow-up report with autopsy findings","volume":"98","author":"Nishijima","year":"2022","journal-title":"Neurology"},{"key":"key20220826100530_b16-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20220826100530_b17-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: A systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"key20220826100530_b18-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: Breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"key20220826100530_b19-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"l1296","DOI":"10.1136\/bmj.l1296","article-title":"Glasgow coma scale explained","volume":"365","author":"Mehta","year":"2019","journal-title":"BMJ"},{"key":"key20220826100530_b20-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"key20220826100530_b21-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"},{"key":"key20220826100530_b22-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key20220826100530_b23-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"key20220826100530_b24-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20220826100530_b25-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20220826100530_b26-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20220826100530_b27-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jtho.2016.05.028","article-title":"Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC","volume":"11","author":"Arriola","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20220826100530_b28-ol-24-03-13444","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00311","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:05:37Z","timestamp":1661497537000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13444","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"324"}}